Probiotic Prawn Oral Immunotherapy (ProPIT) for Treatment of Prawn Allergy

益生菌虾口服免疫疗法 (ProPIT) 用于治疗虾过敏

• 批准号: nhmrc : 1144965
• 负责人: Prof Andreas Lopata
• 金额: $ 126.12万
• 依托单位: Murdoch Childrens Research Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/probiotic-prawn-oral-prawn-allergy/1320319
• 关键词: Probiotic; Prawn; Oral; Immunotherapy; ProPIT

A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.

需要一种“治愈性”食物过敏治疗来预防死亡和改善护理。我们最近发现益生菌花生口服免疫疗法（PPOIT）对治疗花生过敏非常有效。82%的PPOIT治疗儿童获得耐受性，而安慰剂组为4%。我们现在将测试组合益生菌食品OIT方法用于治疗对虾过敏。如果成功，我们将确定第一种对虾过敏治疗方法和其他食物过敏的平台治疗方法。